KIDRON Capital Assets Announces First Close of Women's Health VC Fund
Untapped Potential, Significant Returns: The first-of-its-kind fund with a presence in Israel, is led by expert female General Partners and targets untapped opportunities in Women's Health across Europe, the USA, and Israel.
TEL AVIV, Israel, April 9, 2024 /PRNewswire/ -- We are thrilled to announce the successful first close of KIDRON Capital Assets, marking a significant milestone as the premier venture capital fund dedicated to Women's Health. Led by two female General Partners with profound investment and industry expertise in the HealthTech sector, KIDRON is uniquely positioned at the intersection of groundbreaking healthcare innovation and untapped investment potential. Our primary mission is to generate superb returns for our investors by capitalizing on the extensive, yet often overlooked, opportunities within the women's health sector.
Our investment reach extends across three key geographies?Europe, the USA, and Israel. KIDRON's portfolio encompasses a diverse array of sectors, including medical devices, diagnostics, digital health, therapeutics, and services. This strategic diversity ensures our ability to impact various facets of women's health while driving innovation, positive change, and outstanding returns for our investors.
The fund has made inaugural investments in groundbreaking U.S.-based companies, all poised to generate substantial returns:
Beyond Medicine: Pioneering the longevity space with cutting-edge solutions redefining human health span by targeting mitochondrial health, improving skin rejuvenation and alleviating menopausal symptoms.
Portal: Revolutionizing a $1B market with a simplified, scalable solution for oncology clinics, backed by a proven team with six exits to giants like Medtronic and BD, Portal's approach enhances access to care and quality of life for women facing cancer, signaling strong potential for investor gains.
Renal Guard: The only clinically validated solution to prevent Acute Kidney Injury (AKI), a risk heightened for women during cardiac surgeries. With its CE approval, initial sales and investigation in the US, Renal Guard is redefining standards of care, ensuring women's health and safety during common surgical procedures, while promising substantial returns for investors.
Invest in the Future of Women's Health: Partner with KIDRON Capital to Generate High Returns and Make a Difference.
In the news release, Nomic Unveils Bitcoin Liquid Staking Token Powered by Babylon's Bitcoin Staking Protocol, issued 10-Apr-2024 by Nomic DAO Foundation over PR Newswire, we are advised by the company that the dateline should read "GEORGE TOWN,...
Westshore Terminals Investment Corporation (the "Corporation") announced today that it has filed its earnings report for the first quarter ended March 31, 2024 and related management's discussion and analysis with the Canadian security regulatory...
Galway Metals Inc. ("Galway" or the "Corporation") is pleased to announce that further to its press release dated April 25, 2024, it has closed the second and final tranche of its non-brokered private placement (the "Private Placement"). The second...
S&P MidCap 400 constituent Vistra Corp. will replace Pioneer Natural Resources Co. in the S&P 500, S&P SmallCap 600 constituent Aaon Inc. (NASD: AAON) will replace Vistra in the S&P MidCap 400, and Marathon Digital Holdings Inc. (NASD: MARA) will...
Vizsla Silver Corp. ("Vizsla Silver" or the "Company") is pleased to announce that it has now issued 448,137 common shares (the "Consideration Shares") for the previously announced asset purchase agreement (the "Acquisition Agreement") dated March...